



Press release, September 1, 2016

Diamyd Medical appoints new head of Clinical Development

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that Martina Widman, M.Sc. in Mechanical Engineering from the Royal Institute of Technology in Stockholm and employed in Diamyd Medical since 2008, as of September 1 succeeds Erika Hillborg as Director of Clinical Development.

“I warmly thank Erika for her ten years in the company,” says Ulf Hannelius, President and CEO of Diamyd Medical. “Erika built the clinical operations at Diamyd Medical and under her leadership, several clinical studies skillfully and cost effectively were conducted in the US and in Europe. Her efforts have been extremely important in Diamyd Medical's development.”

“It feels sad to leave Diamyd Medical,” says Erika Hillborg. “These years have been amazing and intensely fun and stimulating. Now is the right time for me to hand over and move on to new projects.”

Erika Hillborg is succeeded by Martina Widman, M.Sc. in Mechanical Engineering from the Royal Institute of Technology in Stockholm with a specialization in Biomedical Engineering. Martina Widman will be a member of Diamyd Medical's management team.

About Diamyd Medical

Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd[®], an Antigen Based Therapy (ABT) based on the exclusively licensed GAD-molecule. The Company's licensed technologies for GABA and Gliadin have also potential to become key pieces of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes, and also certain inflammatory diseases. At this time six clinical studies are ongoing with Diamyd[®]. Diamyd Medical is one of the major shareholders in the stem cell company Cellaviva AB. Stem cells can be expected to be used in Personalized Regenerative Medicine (PRM), for example for restoration of beta cell mass in diabetes patients where the autoimmune component of the disease has been arrested. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical's B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company's Certified Adviser.

For further information, please contact:

Ulf Hannelius, President and CEO

Phone: +46 736 35 42 41. E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68

E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.

This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on September 1, 2016.